Quarterly report pursuant to Section 13 or 15(d)

Stock Based Compensation - Legacy NeuroRx 2016 Omnibus Incentive Plan (Details)

v3.21.2
Stock Based Compensation - Legacy NeuroRx 2016 Omnibus Incentive Plan (Details)
9 Months Ended
Sep. 30, 2021
USD ($)
Vested substitute options  
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Share-based Payment Arrangement, Plan Modification, Incremental Cost $ 1,014,640
Vested substitute options | General and administrative  
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Share-based Payment Arrangement, Plan Modification, Incremental Cost 993,500
Vested substitute options | Research and development  
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Share-based Payment Arrangement, Plan Modification, Incremental Cost 21,140
Unvested substitute options  
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Share-based Payment Arrangement, Plan Modification, Incremental Cost $ 25,877,473